A promising new cancer marker: Long noncoding RNA EGFR-AS1
Cancer consists of a group of diseases with the salient properties of an uncontrolled cell cycle, metastasis, and evasion of the immune response, mainly driven by the genomic instability of somatic cells and the physicochemical environment. Long noncoding RNAs (lncRNAs) are defined as noncoding RNAs...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1130472/full |
| _version_ | 1797895092056358912 |
|---|---|
| author | Danhua Zhu Xiaoxi Ouyang Yanhong Zhang Xiaopeng Yu Kunkai Su Lanjuan Li |
| author_facet | Danhua Zhu Xiaoxi Ouyang Yanhong Zhang Xiaopeng Yu Kunkai Su Lanjuan Li |
| author_sort | Danhua Zhu |
| collection | DOAJ |
| description | Cancer consists of a group of diseases with the salient properties of an uncontrolled cell cycle, metastasis, and evasion of the immune response, mainly driven by the genomic instability of somatic cells and the physicochemical environment. Long noncoding RNAs (lncRNAs) are defined as noncoding RNAs with a length of more than 200 nucleotides. LncRNA dysregulation participates in diverse disease types and is tightly associated with patient clinical features, such as age, disease stage, and prognosis. In addition, an increasing number of lncRNAs have been confirmed to regulate a series of biological and pathological processes through numerous mechanisms. The lncRNA epidermal growth factor receptor antisense RNA 1 (EGFR-AS1) was recently discovered to be aberrantly expressed in many types of diseases, particularly in cancers. A high level of EGFR-AS1 was demonstrated to correlate with multiple patient clinical characteristics. More importantly, EGFR-AS1 was found to be involved in the mediation of various cellular activities, including cell proliferation, invasion, migration, chemosensitivity, and stemness. Therefore, EGFR-AS1 is a promising marker for cancer management. In this review, we introduce the expression profile, molecular mechanisms, biological functions, and clinical value of EGFR-AS1 in cancers. |
| first_indexed | 2024-04-10T07:20:59Z |
| format | Article |
| id | doaj.art-9d2d645853634c5281f4444a3ea3f317 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T07:20:59Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-9d2d645853634c5281f4444a3ea3f3172023-02-24T12:38:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-02-011310.3389/fonc.2023.11304721130472A promising new cancer marker: Long noncoding RNA EGFR-AS1Danhua ZhuXiaoxi OuyangYanhong ZhangXiaopeng YuKunkai SuLanjuan LiCancer consists of a group of diseases with the salient properties of an uncontrolled cell cycle, metastasis, and evasion of the immune response, mainly driven by the genomic instability of somatic cells and the physicochemical environment. Long noncoding RNAs (lncRNAs) are defined as noncoding RNAs with a length of more than 200 nucleotides. LncRNA dysregulation participates in diverse disease types and is tightly associated with patient clinical features, such as age, disease stage, and prognosis. In addition, an increasing number of lncRNAs have been confirmed to regulate a series of biological and pathological processes through numerous mechanisms. The lncRNA epidermal growth factor receptor antisense RNA 1 (EGFR-AS1) was recently discovered to be aberrantly expressed in many types of diseases, particularly in cancers. A high level of EGFR-AS1 was demonstrated to correlate with multiple patient clinical characteristics. More importantly, EGFR-AS1 was found to be involved in the mediation of various cellular activities, including cell proliferation, invasion, migration, chemosensitivity, and stemness. Therefore, EGFR-AS1 is a promising marker for cancer management. In this review, we introduce the expression profile, molecular mechanisms, biological functions, and clinical value of EGFR-AS1 in cancers.https://www.frontiersin.org/articles/10.3389/fonc.2023.1130472/fulllncRNAEGFR-AS1expressionfunctionsclinical values |
| spellingShingle | Danhua Zhu Xiaoxi Ouyang Yanhong Zhang Xiaopeng Yu Kunkai Su Lanjuan Li A promising new cancer marker: Long noncoding RNA EGFR-AS1 Frontiers in Oncology lncRNA EGFR-AS1 expression functions clinical values |
| title | A promising new cancer marker: Long noncoding RNA EGFR-AS1 |
| title_full | A promising new cancer marker: Long noncoding RNA EGFR-AS1 |
| title_fullStr | A promising new cancer marker: Long noncoding RNA EGFR-AS1 |
| title_full_unstemmed | A promising new cancer marker: Long noncoding RNA EGFR-AS1 |
| title_short | A promising new cancer marker: Long noncoding RNA EGFR-AS1 |
| title_sort | promising new cancer marker long noncoding rna egfr as1 |
| topic | lncRNA EGFR-AS1 expression functions clinical values |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1130472/full |
| work_keys_str_mv | AT danhuazhu apromisingnewcancermarkerlongnoncodingrnaegfras1 AT xiaoxiouyang apromisingnewcancermarkerlongnoncodingrnaegfras1 AT yanhongzhang apromisingnewcancermarkerlongnoncodingrnaegfras1 AT xiaopengyu apromisingnewcancermarkerlongnoncodingrnaegfras1 AT kunkaisu apromisingnewcancermarkerlongnoncodingrnaegfras1 AT lanjuanli apromisingnewcancermarkerlongnoncodingrnaegfras1 AT danhuazhu promisingnewcancermarkerlongnoncodingrnaegfras1 AT xiaoxiouyang promisingnewcancermarkerlongnoncodingrnaegfras1 AT yanhongzhang promisingnewcancermarkerlongnoncodingrnaegfras1 AT xiaopengyu promisingnewcancermarkerlongnoncodingrnaegfras1 AT kunkaisu promisingnewcancermarkerlongnoncodingrnaegfras1 AT lanjuanli promisingnewcancermarkerlongnoncodingrnaegfras1 |